(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...

EAU 2026: Preliminary Results of a Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Combination with Radiotherapy for Adjuvant Therapy in Upper Tract Urothelial ...

Dr. Aleksander Słusarczyk presented the clinical case of a 75-year-old woman who presented with a two-month history of hematuria. Her medical history was notable for diabetes, prior myocardial ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...

The CAIX targeting radiotracer 68 Ga-C1 was developed and validated through in vitro assays. Initially, the investigators ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...

Dr. Matthew Galsky participated in the Case-based panel discussion Beyond platinum: Evolving frontlines in mUC and discussed where ADCs fit in the sequencing. Dr. Galsky began by emphasizing the rapid ...

ZIRCON-X was designed as a post-hoc analysis of imaging data collected in the ZIRCON trial to evaluate how the incorporation of 89 Zr-girentuximab PET imaging could influence clinical management ...

The median fraction of the gland reaching ablative temperatures on intra-procedural MRI thermometry was 78% (IQR 71-85), with 68% of cases comprising whole gland ablation and 32% sub-total ablation: ...